| 12/20/2019 | SP | New Issue: JPMorgan sells $1 million yield notes with contingent digital return on Acadia Pharmaceuticals
|
| 12/12/2012 | PP | Acadia Pharmaceuticals negotiates $84.17 million placement of shares
|
| 3/30/2012 | PP | Acadia Pharmaceuticals negotiates $20 million at-the-market offering
|
| 1/10/2011 | PP | Acadia Pharmaceuticals to raise $15 million via placement of units
|
| 9/24/2010 | PP | Acadia revises price for stock sales in Kingsbridge financing facility
|
| 8/5/2008 | PP | New Issue: Acadia negotiates $60 million equity financing with Kingsbridge
|
| 8/5/2008 | PP | Market Commentary: Acadia gets $60 million; EPIX arranges $50 million; RoomLinX, Admiralty advance funding efforts
|
| 4/27/2007 | SP | New Issue: ABN sells $1.05 million 16% knock-in notes linked to Acadia Pharmaceuticals
|
| 4/4/2007 | SP | ABN Amro plans 16% reverse exchangeable securities linked to Acadia Pharmaceuticals
|
| 3/19/2007 | SS | Market Commentary: EGL, Triad up on higher offers; Take-Two better; Acadia zooms; Todco drives drillers; lenders off
|
| 11/7/2006 | BT | Acadia kept at market outperform by JMP
|
| 11/6/2006 | BT | Acadia third-quarter net loss improves to $11.3 million, revenues fall
|
| 9/25/2006 | BT | Acadia accelerates ACP-103 phase 2 schizophrenia trial
|
| 9/8/2006 | BT | Acadia settles civil suit; litigation fees total $9.1 million
|
| 8/16/2006 | BT | Market Commentary: CV Therapeutics gains after pricing follow-on; Acadia adds again; Accentia slides
|
| 8/15/2006 | BT | Market Commentary: Acadia gains; Shire, Barr, New River up on settlement; Novavax rises; Vasogen off
|
| 8/11/2006 | BT | Acadia expects to begin phase 3 clinical trials of ACP-103 for Parkinson's disease in early 2007
|
| 7/13/2006 | BT | Market Commentary: Nastech loses 15% on FDA snub; Novavax retreats; Anadys moves up; Acadia slumps; Illumina lifted
|
| 7/13/2006 | BT | Acadia says results from three trials show effectiveness of ACP-104 in treatment of schizophrenia
|
| 7/10/2006 | BT | Market Commentary: Connetics drops 33% on lowered forecast; Antigenics off 5%; Depomed off; Acadia gains
|
| 6/8/2006 | BT | Market Commentary: AtheroGenics drops; Nastech up; Novavax, BioCryst decline; Sirna slides; Acadia off; XenoPort drops
|
| 5/11/2006 | BT | Acadia stays at market outperform by JMP
|
| 4/28/2006 | BT | New Issue: Acadia raises $59.4 million in follow-on of 4.95 million shares at $12 each vs. $12.72 close
|
| 4/27/2006 | BT | Market Commentary: Acadia sinks with stock float on deck; Human Genome gains 9%; Isis gains big on data; Ark rises
|
| 4/24/2006 | BT | Acadia plans follow-on offering of 4.95 million shares via Banc of America, Lehman
|
| 4/24/2006 | BT | Market Commentary: DOV, Discovery Labs off huge after close; 3 deals emerge; GW up big; Ariad off on Amgen suit
|
| 4/19/2006 | BT | Acadia's ACP-103 increases deep sleep in insomnia
|
| 3/30/2006 | BT | Acadia reiterated at market outperform by JMP
|
| 3/24/2006 | BT | JMP reiterates Acadia at market outperform
|
| 3/23/2006 | BT | Acadia announces positive phase 2 trial results for treatment-induced psychosis in Parkinson's patients
|
| 3/6/2006 | BT | Acadia, Allergan extend research agreement to 2008
|
| 3/2/2006 | BT | Acadia kept at market outperform by JMP
|
| 2/21/2006 | BT | Acadia picks development candidate for testosterone deficiency, finds appetite-related mechanism
|
| 2/15/2006 | BT | JMP reiterates Acadia at market outperform
|
| 1/18/2006 | BT | Acadia Pharmaceuticals files $75 million stock shelf
|
| 1/18/2006 | BT | JMP says select small-, mid-cap biotech stocks look promising
|
| 1/18/2006 | BT | Market Commentary: KV Pharmaceutical stock up on patent ruling; biotech offerings take a back seat to tech market
|
| 1/17/2006 | BT | Market Commentary: Arena gains in face of follow-on deal; deCODE spikes on diabetes discovery; Acadia, Sepracor firm
|
| 1/17/2006 | PP | Market Commentary: Aksys secures $20 million equity line; PIPE volume booms after lull
|
| 1/17/2006 | BTPP | New Issue: Acadia Pharmaceuticals raises $10 million in stock sale
|
| 12/15/2005 | BT | Acadia says research published on isoform-selective retinoic acid receptors, may lead to drugs
|
| 12/2/2005 | BT | JMP reiterates Acadia at market outperform
|
| 12/1/2005 | BT | Acadia's ACP-103 reduces restlessness in schizophrenia patients in phase 2 study
|
| 11/11/2005 | BT | JMP ups Acadia's target price to $15
|
| 11/10/2005 | BT | Acadia Pharmaceuticals' ACP-104 for treatment of Schizophrenia safe and well tolerated, study shows
|
| 8/11/2005 | BT | Acadia kept by JMP at market outperform
|
| 6/22/2005 | BT | Acadia Pharmaceuticals calls Parkinson's disease treatment trial 'encouraging'
|
| 4/15/2005 | PP | Market Commentary: Veracel's C$114 million deal seen selling well; oil prices soar and may help volume
|
| 4/15/2005 | PP | New Issue: Acadia raises $36.15 million in private placement of stock
|
